Skip to main content

Bromocriptine Disease Interactions

There are 4 disease interactions with bromocriptine.

Major

Dopamine agonists (applies to bromocriptine) cardiac disease

Major Potential Hazard, Low plausibility. Applicable conditions: Cardiovascular Disease

Cardiac irregularities occur infrequently in patients on dopamine agonists. The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care. Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.

References

  1. Shah PK, Amin DK, Horn E (1985) "Adverse clinical and hemodynamic effects of oral levodopa in chronic congestive heart failure." Am Heart J, 110, p. 488-9
  2. Benaim ME (1972) "Levodopa and arrhythmias." Br Med J, 4, p. 50-1
  3. Broderick G, Rajfer SI (1989) "The use of levodopa, an oral dopamine precursor, in congestive heart failure." Basic Res Cardiol, 84, p. 187-90
  4. Chamsi-Pasha H, Horsley M, Barnes PC (1989) "Levodopa and congestive cardiomyopathy." Br J Hosp Med, 41, p. 489
  5. (2001) "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals
  6. (2001) "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals
View all 6 references
Major

Dopamine agonists (applies to bromocriptine) hypotension

Major Potential Hazard, High plausibility.

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.

References

  1. Hoehn MM (1975) "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol, 32, p. 50-1
  2. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y (1990) "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol, 30, p. 194-9
  3. (2001) "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn
  4. (2001) "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals
  5. (2001) "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals
  6. (2001) "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim
  7. (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
  8. (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
  9. (2006) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA
  10. (2007) "Product Information. Neupro (rotigotine)." Schwarz Pharma
  11. (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
View all 11 references
Major

Dopamine agonists (applies to bromocriptine) psychoses/depression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Psychosis

The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality. Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.

References

  1. Ko GN, Leckman JF, Heninger GR (1981) "Induction of rapid mood cycling during L-dopa treatment in a bipolar patient." Am J Psychiatry, 138, p. 1624-5
  2. Ryback RS, Schwab RS (1971) "Manic response to levodopa therapy. Report of a case." N Engl J Med, 285, p. 788-9
  3. Banerjee AK, Falkai PG, Savidge M (1989) "Visual hallucinations in the elderly associated with the use of levodopa." Postgrad Med J, 65, p. 358-61
  4. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D (1993) ""Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy." Acta Neurol Scand, 87, p. 14-8
  5. Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL (1984) "Psychiatric complications of levodopa therapy of Parkinson's disease." Adv Neurol, 40, p. 271-7
  6. Glantz RH, Bieliauskas L, Paleologos N (1987) "Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease." Adv Neurol, 45, p. 417-20
  7. Friedman JH (1991) "The management of the levodopa psychoses." Clin Neuropharmacol, 14, p. 283-95
  8. Harsch HH, Miller M, Young LD (1985) "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol, 5, p. 338-9
  9. Maricle RA, Nutt JG, Carter JH (1995) "Mood and anxiety fluctuation in parkinson's disease associated with levodopa infusion: preliminary findings." Mov Disord, 10, p. 329-32
  10. (2001) "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals
  11. (2001) "Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals
View all 11 references
Major

Dopaminergic antiparkinson agents (applies to bromocriptine) psychosis

Major Potential Hazard, Moderate plausibility.

Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis. Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of these drugs.

References

  1. (2001) "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn
  2. (2001) "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim
  3. (2001) "Product Information. Requip (ropinirole)." SmithKline Beecham
  4. (2001) "Product Information. Comtan (entacapone)." Novartis Pharmaceuticals
  5. (2001) "Product Information. Lodosyn (carbidopa)." DuPont Pharma
  6. (2006) "Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA
  7. (2007) "Product Information. Neupro (rotigotine)." Schwarz Pharma
  8. (2017) "Product Information. Xadago (safinamide)." US WorldMeds LLC
View all 8 references

Bromocriptine drug interactions

There are 444 drug interactions with bromocriptine.

Bromocriptine alcohol/food interactions

There is 1 alcohol/food interaction with bromocriptine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.